Is quantitative coronary angiography reliable in assessing the lumen gain after treatment with the everolimus-eluting bioresorbable polylactide scaffold?
EuroIntervention 2016;12:e998-e1008 published online e-edition October 2016. DOI: 10.4244/EIJV12I8A163
Yohei Sotomi1, MD; Yoshinobu Onuma2,3, MD, PhD; Pannipa Suwannasom1,2,4, MD; Hiroki Tateishi2, MD, PhD; Erhan Tenekecioglu2, MD; Yaping Zeng2, MD, PhD; Rafael Cavalcante2, MD, PhD; Hans Jonker3, BSc; Jouke Dijkstra5, PhD; Nicolas Foin6, MSc, PhD; Jaryl Ng Chen Koon6, B.Eng; Carlos Collet1, MD; Robbert J. de Winter1, MD, PhD; Joanna J. Wykrzykowska1, MD, PhD; Gregg W. Stone7, MD; Jeffrey J. Popma8, MD, PhD; Ken Kozuma9, MD, PhD; Kengo Tanabe10, MD, PhD; Pat
1. Academic Medical Center, University of Amsterdam, Amsterdam, The Netherlands; 2. Thoraxcenter, Erasmus Medical Center, Rotterdam, The Netherlands; 3. Cardialysis, Rotterdam, The Netherlands; 4. Northern Region Heart Center, Faculty of Medicine, Chiang
Aims: The current study aimed to assess the difference in lumen dimension measurements between optical coherence tomography (OCT) and quantitative coronary angiography (QCA) in the polyme
